Sanofi sees stand-alone Japan generics biz complementing JV
This article was originally published in Scrip
Reflecting its broader interests in the sector around the globe, Sanofi will independently enter the Japanese generic market later this year with the launch of versions of the antihypertensive valsartan (Novartis's Diovan) and zoledronic acid (Novartis's Zometa).
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.